RxDoctor Payments Data

Elena Grebenciucova, MD

Neurology · Chicago, ILNPI 1467708305

Payments from drug & device makers

$139,301in general payments, 2019–2025

Across 81 payments — averaging $1719.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$48K
  • Genentech, Inc.$39K
  • TG Therapeutics, Inc.$25K
  • Amgen$13K
  • Genentech USA, Inc.$11K
  • Eli Lilly$4K
  • plus $150 from 1 others

What the payments were for

  • Consulting fees$25,05125%
  • Speaking & faculty fees$71,59570%
  • Travel & lodging$3,2173%
  • Food & beverage$2,1382%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AstraZeneca39$48,246
Genentech, Inc.4$39,065
TG Therapeutics, Inc.20$24,529
Amgen(2 entities)7$12,705
Genentech USA, Inc.9$10,931
Eli Lilly1$3,675
Biogen1$150

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$139,301 in reported general payments places this provider in the 90th percentile of 790 neurology providers in Illinois.

See all neurology providers in Illinois

Medicare billing

Part B allowed, 2024
$1,422,301
Medicare patients
129
Services billed
82,393

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EnspryngSatralizumab-Mwge24$412,432
Kesimpta PenOfatumumab24$208,878
CopaxoneGlatiramer Acetate25$158,271
VumerityDiroximel Fumarate12$97,305
Azathioprine11$11,274
Dimethyl Fumarate19$3,439
Mycophenolate Mofetil39$3,388
Baclofen99$2,344
Gabapentin44$656
Carbamazepine ErCarbamazepine12$557
Duloxetine Hcl23$534
Prednisone35$383
MethotrexateMethotrexate Sodium20$189
Pregabalin14$162
Amitriptyline Hcl18$134

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Genentech USA, Inc.Enspryng$10,931$412,43224 claims
BiogenVumerity$150$97,30512 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 790 neurology providers in Illinois.

Other neurology in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →